Background: Rattlesnake envenomation is an important problem in the United States, and the management of
R attlesnake envenomation remains an important health problem, with nearly 9,000 patients treated for snakebite annually in the United States. 1 Although mortality is low, rattlesnake envenomations are associated with significant morbidity and cost. The management of such envenomations ideally involves intensive evaluation and reassessment. In addition, specific postdischarge instructions and reevaluations are recommended. 1 In 2015, poison information specialists at U.S. poison control centers assisted health care facilities in the management of more than 3,500 snakebites. 2 Medical toxicologists, physicians with specialized training in envenomations, frequently provide guidance to the poison information specialists remotely managing these patients. Additionally, when available as a consulting or admitting service, medical toxicologists provide direct care at the bedside of envenomated patients. The involvement of a toxicologist in the care of poisoned patients in general is associated with reduced length of stay (LOS) and possibly reduced health care costs. [3] [4] [5] [6] It is unclear, however, what role a medical toxicology service (MTS), in which a medical toxicologist is providing direct patient care, provides in patients with rattlesnake envenomations. The primary objective of this study was to evaluate the impact of a MTS on the LOS of patients with rattlesnake envenomations.
METHODS
This study is a retrospective study of patients evaluated at six different medical centers in California following rattlesnake envenomation. These centers include two university-affiliated teaching hospitals, two community teaching hospitals, one university-affiliated nonteaching hospital, and one community nonteaching hospital. Each of these centers established a MTS between 2011 and 2015. At each of these centers, the toxicologist serves as a consultant and has formal consulting privileges. In all but one of the centers, the toxicologist did write orders for antivenom as a consultant and managed the issues related to the envenomation. Consults were provided by five independent toxicology groups at the six hospitals. Eligible patients were included if they presented after a known or suspected rattlesnake envenomation in the 2 years before (pre-MTS) or after (post-MTS) a toxicology service was created. Patients were identified via search of ICD-9 (E905.0) codes. Bites due to known nonvenomous snakes (e.g., pet king snake) were excluded. Definitive confirmation of the snake was not required. In addition, if, upon reviewing the record, the bite was clearly not due to a snake, but simply coded based on ICD-9 code, the record was excluded. This study was performed as an intent-to-treat analysis, such that each patient in the post-MTS period was included, even if toxicology was not consulted. The study was approved by the institutional review board at each of the participating medical centers.
Study Definitions
Length of stay was calculated in hours from presentation to the emergency department (ED) until discharge from the hospital. Maintenance therapy was defined as a scheduled order for three doses of antivenom, each six hours apart. Bleeding was defined as any bleeding beyond local oozing from the bite site. Poison control was considered to be involved if discussion with poison control was documented at any point during the patient's hospital stay.
Data Abstraction
Data were collected on a predesigned data abstraction sheet by one member of the study team at each institution. Each reviewer received a brief training on data abstraction to ensure the abstraction was uniform at each site. The investigators were blinded to the study hypothesis. After data collection, data were entered into an Excel Spreadsheet (Microsoft Corp.). Baseline data abstracted from the medical record included age, sex, year of admission, study time period (preinitiation or postinitiation of MTS), location of the bite, past medical history, and use of antiplatelet or anticoagulant medications. The patient's LOS, initial, nadir, maximal, and final laboratory studies (prothrombin time, platelets, and fibrinogen), incidence of bleeding, and involvement of a poison control center were recorded. Treatment with antivenom, nonsteroidal anti-inflammatory drugs, antibiotics, blood products, and incidence of surgical intervention was abstracted. Finally, LOS, administration of rattlesnake-specific discharge instructions, and readmission for complications related to the snakebite were recorded.
Outcome Measures
The primary outcome in this study was hospital LOS. Additional outcomes evaluated included total number of vials of antivenom used; maximum and nadir laboratory values; administration of blood products, antibiotics, and nonsteroidal anti-inflammatory drugs; incidence of surgical intervention; and bleeding and readmission for snakebite-related complications.
Data Analysis
The data from these six medical centers were pooled and analyzed in a before/after model. Continuous data, all of which were found to be nonnormal by ShapiroWilk testing, were analyzed for central tendency using median and interquartile range (IQR). Proportions were reported with 95% confidence intervals (CIs), which were calculated using binomial exact methods.
Univariate analysis was utilized to assess whether there were apparent changes in patient complexity or acuity between the study period's pre-MTS and MTS groups, to inform decisions as to whether any differences were identified that prompted a need for multivariate regression modeling.
Kruskal-Wallis nonparametric methods were utilized for initial analysis of continuous variables, and chi-square analysis and Fisher's exact testing (when any cell value fell below five) were used for categorical variables. When significant differences were identified in univariate testing, standard epidemiologic measures were calculated. The measures of relative risk were the risk ratio and risk difference (with the inverse of the latter used to calculate number needed to treat).
An a priori decision was made to analyze the primary endpoint (LOS) with nonparametric KruskalWallis testing first. Then, only if the nonparametric p-value was significant, with parametric techniques (the t-test) to accurately estimate the effect magnitude. This approach is conservative, as it avoids use of techniques such as bootstrapping (for 95% CIs for medians) and if anything would underestimate the significance of any MTS effect on LOS. [7] [8] [9] To assess the median differences in the pre-and post-MTS periods for each of the MTS services, two approaches were taken. First, the LOS for the pre-and post-MTS periods were tabulated for each of the five MTS groups (five services covered six hospitals). Next, the overall group of pre-and post-MTS periods' LOS data were tabulated. The overall pre-vs. post-MTS period LOS results were compared using Wilcoxon rank-sum testing, to assess the null hypothesis of zero difference between the medians of the two groups. To provide conservative calculations, Stata's cendif procedure was used, to provide a robust calculation of the (Hodges-Lehmann) median difference (with 95% CI) between the pre-and post-MTS periods, clustered on MTS group
Variables assessed to determine whether patient characteristics were similar between the pre-MTS and MTS groups included patient demographics and medical history, information regarding diabetes status, anticoagulation therapy, and known liver disease. Additional information used to assess patient acuity at index-visit ED presentation included the initial coagulation laboratory parameters, number of antivenom vials in first treatment, and bite location (categorized as to hand, foot, nonhand or nonfoot extremity, or other location).
RESULTS
A total of 302 patients were identified. Upon review of the records, two patients were bitten or stung by noncrotalidae and thus were excluded. Thus, the final population included 300 patients. There were 169 patients in the pre-MTS cohort and 131 patients in the post-MTS cohort. A toxicologist was involved in none of the cases in the pre-MTS cohort, whereas a toxicologist was involved in 99 (76%) cases in the post-MTS group. Overall, males accounted for 228 (76%) of all subjects. The majority of the bites were to the hand (60.3%), foot (20%), and nonfoot lower extremity (15.3%). The median (IQR) age was 44 (22-55.5) years.
There were no significant differences observed in the baseline parameters between the two groups. Shock on presentation was uncommon (2.4% vs 2.3% in the pre-MTS and post-MTS groups, respectively). Similarly, there was no difference in initial hematologic parameters between the two groups (see Table 1 ). Based on these negative findings in univariate analysis, in accordance with a priori methods planning, there was no requirement to proceed with multivariate analysis to assess a possible association between MTS status and LOS.
LOS was significantly shorter for post-MTS compared to pre-MTS cases (48. However, the use of maintenance dosing of antivenom was somewhat higher in the post-MTS group compared with the pre-MTS group, albeit still low in both group (31.5% vs. 17.8%; 95% CI = 3.42%-24%) Antibiotics, however, were administered more often in the pre-MTS group (18.3% vs. 10.0%; p = 0.04, risk ratio = 1.8, 95% CI = 1.0-3.4). There were no fatalities in either group.
Twenty-one patients (12.4%) of the pre-MTS group were readmitted compared with 18 (13.9%) in the post MTS group (p = 0.718; see Table 2 for complete outcome results).
DISCUSSION
This study demonstrated the development of a MTS was associated with decreased LOS, with similar rates of antivenom administration and readmission rates. While the study was retrospective, the available data suggest little, if any, clinically important difference in baseline characteristics between the two groups. None of the demographic, laboratory, or medical parameters ACADEMIC EMERGENCY MEDICINE • August 2018, Vol. 25, No. 8 • www.aemj.org assessed between the two groups with respect to initial presentation differed significantly. While the apparent similarity of the two groups with respect to all assessed parameters does not eliminate the possibility of residual confounding, we find no evidence of such. Furthermore, the magnitude of the LOS reduction associated with a MTS presence is such that it seems unlikely explainable by unmeasured variables. The implementation of the MTS occurred at different years in different hospitals. Thus, it is unlikely that the decreased LOS was the result of a national change in practice management.
Antibiotics are not routinely indicated for crotaline bites in North America. 10 Implementation of a MTS was associated with a reduction in antibiotic therapy (18% vs. 10%). Diffuse bleeding or shock on presentation, n (%) 4 (2.4% of 169) 3 (2.3% of 130)* 1.00
Initial vials of therapy, median (IQR) 6 (4-6) 6 (4-6) .831 IQR = interquartile range; MTS = medical toxicology service. *Data were missing for one patient in the MTS group for this parameter. A denominator of 130 was used.
The most important finding was that the a priori primary endpoint, LOS, was shorter for the MTS cases than the pre-MTS cases. The difference was clinically, administratively, and statistically significant. The MTS group status on univariate analysis was associated with nearly a full day's shorter LOS (>21 hours). Such LOS reductions along these lines could be investigated as a major contributor to the cost-effectiveness of instituting MTS in hospitals such as the study centers. Importantly, the reduction in LOS associated with a MTS was associated with similar readmission rates. While it is possible that readmissions would be missed if the patient presented to a hospital outside of the study site, it is unlikely this would be significantly different in the pre-versus post-MTS. However, one could imagine a case that the readmission rate would be higher in the post-MTS group, as the toxicologists were following the patients as outpatients, whereas a hospitalist would typically not follow the patient as an outpatient. In this study, several patients in the post-MTS group were admitted to a hospitalist and the toxicologist was not consulted. Thus, if consults were obtained on each patient in the post-MTS group, the results would likely be further magnified.
Given there is a reduction in the LOS and a reduction in unnecessary treatments (e.g., antibiotics) while not increasing readmission rates, an argument can be made that the involvement of a medical toxicologist in the care of a rattlesnake bite patient is associated with improved quality of care.
The exact cost savings are difficult to determine and dependent on multiple variables, including the number of toxicologists, the volume of patients, etc. However, in one study, care of a poisoned patient by a toxicologist was associated with a cost savings of more than $1000 per patient. 3 It is assumed, but not known definitively, that the involvement of a toxicologist in a rattlesnake bite patient would be associated with a significant cost savings. While there was a statistically significant decrease in the LOS for patients in the MTS group, the study was not designed or intended to perform a cost analysis of a MTS or the overall costs associated with rattlesnake-envenomated patients. As increased healthcare pressures exert more influence over hospitalizations and observation, such a prospective study may be of value.
The use of maintenance therapy was greater in the post-MTS group, but still remained relatively uncommon (18% vs. 32%). While one would expect increased use of maintenance antivenom to be associated with an increased LOS, it was not. Perhaps this apparent discrepancy was because the increased level of expertise in the post-MTS period led to greater use in patients who needed it the most. This study is similar to previous studies that have demonstrated potential benefit to a MTS. Curry and colleagues 3 performed a severity-weighted comparison of the cost, LOS, and percent mortality for their admitting service in comparison to the Premier database. The authors found that their toxicology admitting service was associated with decreased LOS and decreased morbidity with the added benefit of cost savings. Chang and colleagues 5 established a MTS at their university-affiliated teaching hospital and examined the LOS in patients admitted with acetaminophen toxicity before and after the service was created. The authors found a significant decreased LOS after a MTS was created. Finally, Lee and colleagues 6 examined the LOS in the 12-month period before and after a toxicology service was created at a major metropolitan teaching hospital in Australia. The authors found creation of the toxicology service resulted in increased number of patients treated while reducing the LOS. While other studies have examined the effect of a toxicologist in the care of an overdose patient, this is the first to examine the effect of a MTS on envenomated patients. Because of variability in administration of antivenom, it was not known, prior to this study, if a toxicologist's involvement in an envenomated patient would be associated with a reduction in the LOS or the readmission rate compared to patients treated without the direct involvement of a toxicologist.
LIMITATIONS
This study is limited by its retrospective nature and, consequently, any conclusions are limited by the quality and completeness of the data in the medical record. However, because the study primarily used continuous variables (e.g., number of hours in a hospital, fibrinogen) and dichotomous variables (e.g., documented surgical procedure or not), we feel that these choices in the data abstracted likely reduced, if not eliminated, abstractor bias, thereby minimizing some of the limitations inherent in a retrospective review. 11 We did not control for poison control center involvement. While this is a potential limitation, given the relatively low involvement in both groups (36 total cases that were evenly distributed between the pre-and post-MTS groups), we do not feel this has a significant impact on our conclusions.
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There were several patients in the post period that were not seen by a toxicologist. An a priori decision was made to analyze these patients based on pre-MTS and post-MTS, rather than involvement or no involvement of a toxicologist. It is impossible to know the benefit is the actual recommendations and presence at the bedside of the toxicologist or just the fact that there is a service and intangible benefits associated with the MTS (e.g., teaching or "curbside" consultations).
CONCLUSION
The implementation of a medical toxicology service was associated with a reduction in length of stay, without a corresponding increase in the amount of antivenom administered or readmission
